Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists

EMBO Journal

Volumn 17, Issue 3, 1998, Pages 765-773

  Nichols, Mark ^a   Rientjes, Jeanette M J ^a   Stewart, A Francis ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Activation function AF 2; Codon substitution mutagenesis; FLP recombinase fusion protein; Steroid receptor

Indexed keywords

ESTROGEN RECEPTOR; HYBRID PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE MUTATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; COS CELLS; DNA NUCLEOTIDYLTRANSFERASES; ESTROGEN ANTAGONISTS; LIGANDS; MOLECULAR SEQUENCE DATA; MUTATION; PC12 CELLS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032472911     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/17.3.765     Document Type: Article

References (30)

1. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K. (eds) (1995) Current Protocols in Molecular Biology, Vols I-III, John Wiley and Sons, Inc., NY, USA
2. Beato, M., Herrlich, P. and Schutz, G. (1996) Steroid hormone receptors: many actors in search of a plot. Cell, 83, 851-857.
3. Berry, M., Metzger, D. and Chambon, P. (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J., 9, 2811-2818.
4. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. and Moras, D. (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha Nature, 375, 377-382.
5. Brzozowski, A.M., Pike, A.C.W., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.-A. and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-758.
6. Chen, J.W., Lee, J. and Jayaram, M. (1992) DNA cleavage in trans by the active site tyrosine during Flp recombination: switching protein partners before exchanging strands. Cell, 69, 647-658.
7. Cormack, B.P. and Struhl, K. (1993) Regional codon randomization: Defining a TATA-binding protein surface required for RNA polymerase III transcription. Science, 262, 244-248.
8. Danielian, P.S., White, R., Lees, J.A. and Parker, M.G. (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J., 11, 1025-1033.
9. Danielian, P.S., White, R., Hoare, S.A., Fawell, S.E. and Parker, M.G. (1993) Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol., 7, 232-240.
10. Dauvois, S. and Parker, M.G. (1993) In Parker, M.G. (ed.) Steroid Hormone Action. Oxford University Press, NY, pp. 167-185.
11. Glaser, S.M., Yelton, D.E. and Huse, W.D. (1992) Antibody engineering by codon-based mutagenesis in a filamentous phage vector system. J. Immunol., 149, 3903-3913.
12. Gronemeyer, H. and Laudet, V. (1995) Transcription factors 3: nuclear receptors. Protein Profile, 2, 1173-1308.
13. Heery, D.M., Kalkhoven, E., Hoare, S. and Parker, M.G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature, 387, 733-736.
14. Horwitz, K.B., Jackson, T.A., Bain, D.L., Richer, J.K., Takimoto, G.S. and Tung, L. (1996) Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10, 1167-1177.
15. Lanz, R.B. and Rusconi, S.A. (1994) A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinol. 135, 2183-2195.
16. Logie, C. and Stewart, A.F. (1995) Ligand-regulated site-specific recombination. Proc. Natl Acad. Sci. USA, 92, 5940-5944.
17. Mahfoudi, A., Roulet, E., Dauvois, S., Parker, M.G. and Wahli, W. (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl Acad. Sci. USA, 92, 4206-4210.
18. McDonnell, D.P., Clemm, D.L., Hermann, T., Goldman, M.E. and Pike, J.W. (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol., 9, 659-669.
19. Metzger, D., Berry, M., Ali, S. and Chambon, P. (1995) Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol., 9, 579-591.
20. Montano, M.M., Muller, V., Trobaugh, A. and Katzenellenbogen, B.S. (1995) The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol., 9, 814-825.
21. Montano, M.M., Ekena, K., Krueger, K.D., Keller, A.L. and Katzenellenbogen, B.S. (1996) Human estrogen receptor ligand activity inversion mutants: Receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol. Endocrinol., 10, 230-242.
22. Nichols, M., Rientjes, J.M.J., Logie, C. and Stewart, A.F. (1997) FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists. Mol. Endocrinol., 11, 950-961.
23. Picard, D. (1994) Regulation of protein function through expression of chimeric proteins. Curr. Opin. Biotechnol., 5, 511-515.
24. Renaud, J.P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H. and Moras, D. (1995) Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature, 378, 681-689.
25. Roux, S., Terouanne, B., Balaguer, P., Jausons-Loffreda, N., Pons, M., Chambon, P., Gronemeyer, H. and Nicolas, J.C. (1996) Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor. Mol. Endocrinol., 10, 1214-1226.
26. Sikorski, R.S. and Hieter, P. (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics, 122, 19-27.
27. Tonetti, D.A. and Jordan, V.C. (1996) Targeted anti-estrogens to treat and prevent diseases in women. Mol. Med. Today, 2, 218-223.
28. Vegeto, E., Allan, G.F., Schrader, W.T., Tsai, M.-J., McDonnell, D.P. and O'Malley, B.W. (1992) The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell, 69, 703-713.
29. Wagner, R.L., Apriletti, J.W., McGrath, M.E., West, B.L., Baxter, J.D. and Fletterick, R.J. (1995) A structural role for hormone in the thyroid hormone receptor. Nature, 378, 690-697.
30. Wurtz, J.M., Bourguet, W., Renaud, J.P., Vivat, V., Chambon, P., Moras, D. and Gronemeyer, H. (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol., 3, 87-94.